BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31125275)

  • 1. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
    Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M
    FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
    Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
    J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.
    Fionda C; Malgarini G; Soriani A; Zingoni A; Cecere F; Iannitto ML; Ricciardi MR; Federico V; Petrucci MT; Santoni A; Cippitelli M
    J Immunol; 2013 Jun; 190(12):6662-72. PubMed ID: 23686482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
    Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
    J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversity and characterization of polymorphic 5' promoter haplotypes of MICA and MICB genes.
    Cox ST; Madrigal JA; Saudemont A
    Tissue Antigens; 2014 Sep; 84(3):293-303. PubMed ID: 24962621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
    Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
    Front Immunol; 2018; 9():926. PubMed ID: 29765374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
    Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
    Front Immunol; 2018; 9():1282. PubMed ID: 29963042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
    Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
    Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulforaphane induces ROS mediated induction of NKG2D ligands in human cancer cell lines and enhances susceptibility to NK cell mediated lysis.
    Amin PJ; Shankar BS
    Life Sci; 2015 Apr; 126():19-27. PubMed ID: 25721293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
    Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
    J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
    Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
    Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
    Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
    J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
    Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
    Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT3 inhibition by STA21 increases cell surface expression of MICB and the release of soluble MICB by gastric adenocarcinoma cells.
    Garrido-Tapia M; Hernández CJ; Ascui G; Kramm K; Morales M; Ga Rate V; Zúñiga R; Bustamante M; Aguillón JC; Catala N D; Ribeiro CH; Molina MAC
    Immunobiology; 2017 Nov; 222(11):1043-1051. PubMed ID: 28578917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
    Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
    Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
    Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
    Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.